PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
Scherber R. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 81 - 81
Studying epigenomics in single cells: what is feasible and what can we learn?
Wills QF. et al, (2015), Epigenomics, 7, 1231 - 1234
Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML
Chowdhury O. et al, (2014), BLOOD, 124
Development and Evaluation of the Clinical Utility of a Next Generation Sequencing (NGS) Tool for Myeloid Disorders
Hamblin A. et al, (2014), BLOOD, 124
Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34-Human Acute Myeloid Leukemia
Quek L. et al, (2014), BLOOD, 124
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.
Harrison CN. et al, (2014), Br J Haematol, 167, 421 - 423
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT. et al, (2014), Br J Haematol, 167, 418 - 420
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
Khan D. et al, (2014), HAEMATOLOGICA, 99, 341 - 341
A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS
Milojkovic D. et al, (2014), HAEMATOLOGICA, 99, 335 - 335
FLT3-ITD INDUCED MYELOPROLIFERATION CAUSES A CELL EXTRINSIC DEPLETION OF HAEMATOPOIETIC STEM CELLS
Mead AJ. et al, (2014), HAEMATOLOGICA, 99, 256 - 256
OUTCOMES FOR MYELOFIBROSIS PATIENTS WHO SWITCHED FROM FEDRATINIB TO RUXOLITINIB THERAPY
Garcia NC. et al, (2014), HAEMATOLOGICA, 99, 670 - 671
Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.
Grover A. et al, (2014), J Exp Med, 211, 181 - 188
Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
Harrison CN. et al, (2014), British Journal of Haematology, 167, 421 - 423
Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Reilly JT. et al, (2014), British Journal of Haematology, 167, 418 - 420